Salix had a $13B offer on the table before accounting problems crashed share price
March 24, 2015 at 14:13 PM EDT
If it hadn’t been for accounting errors, it’s possible Salix Pharmaceuticals (Nasdaq: SLXP) would have been acquired last year for $205 per share, instead of the $173 per share for which it agreed to sell to Valeant Pharmaceuticals International (NYSE: VRX)...
